+33(0)1 42 54 60 64 | contact@welcomeurope.com

H2020 – JTI IMI 2 – 23nd Call for proposals – 2020

To improve the drug development process by supporting more efficient research and development cooperation among academia, SMEs and the biopharmaceutical industry

2020-09-29
95,150,000 euros
Close

Appeal framework

Institution European Commission
Sectors Health
Beneficiaries
Regions European Union
Details

EU member states 
H2020 associated countries


Content reserved for subscribers

Register for free to access the content

Free access to all information

Priorities and funded actions

TOPICS
Open
– IMI2-2020-23-01: Returning Clinical Trial Data to study participants within a GDPR compliant and approved ethical framework    
– IMI2-2020-23-02: Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance    
– IMI2-2020-23-03: A platform for accelerating biomarker discovery and validation to support therapeutics development for neurodegenerative diseases  
– IMI2-2020-23-04: Optimal treatment for patients with solid tumours in Europe through Artificial Intelligence    
– IMI2-2020-23-05: Shortening the path to Rare Disease diagnosis by using newborn genetic screening and digital technologies   
– IMI2-2020-23-06: Behavioural Model of Factors Affecting Patient Adherence

Financement

* Budget per topic:
– IMI2-2020-23-01: 8.19 million euros
– IMI2-2020-23-02: 9.26 million euros
– IMI2-2020-23-03: 19.4 million euros
– IMI2-2020-23-04: 21.86 million euros
– IMI2-2020-23-05: 24.54 million euros
– IMI2-2020-23-06: 11.9 million euros

Test your eligibility

Need help with your public financing ?

Similar news

25 August 2021

Webinar Horizon Europe: Guide to prepare an accurate financial statement on time

Read the article

9 June 2021

Welcomeurope’s new service!

Read the article